ALNYLAM PHARMACEUTICALS, INC. Fair Value, Assets, Level 1 to Level 2 Transfers, Amount
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Fair Value, Assets, Level 1 to Level 2 Transfers, Amount of $0 as of 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount · last filed 2020-08-06
- 2020-06-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2020-03-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2019-12-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2019-09-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
| Period end | Fair Value, Assets, Level 1 to Level 2 Transfers, Amount |
|---|---|
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 |
| 2019-12-31 | $0.00 10-K · filed 2020-02-13 |
| 2019-09-30 | $0.00 10-Q · filed 2019-10-31 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-06 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-13 |
| 2018-09-30 | $0.00 10-Q · filed 2019-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |